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Abstract
Background: The QOL-PCD questionnaire is a recently developed Health Related Quality of Life (HRQoL)
instrument for Primary Ciliary Dyskinesia. The aim of this study was to translate the adult QOL-PCD questionnaire
into Greek language and to conduct psychometric validation to assess its performance.
Methods: Forward translations to Greek and backward translation to English were performed, followed by
cognitive interviews in 12 adult PCD patients. The finalized translated version was administered to a consecutive
sample of 31 adult, Greek speaking PCD patients in Cyprus for psychometric validation, which included assessment
of internal consistency, test-retest reliability, construct and convergent validity. Internal consistency was assessed by
Cronbach’s alpha test in terms of the overall and sub-scales. Test-retest reliability was assessed by repeat
administration of the questionnaire within 2 weeks and calculation of the intra-class correlation (ICC). Construct
validity was assessed by comparing different groups of patients based on a-priori hypotheses and convergent
validity was evaluated by examining associations between the QOL-PCD and SF-36 questionnaires.
Results: Moderate to good internal consistency was observed (Cronbach’s α: 0.46–0.88 across sub-scales) and test-
retest reliability assessment demonstrated good repeatability for most scales (ICC: 0.67–0.91 across subscales).
Patients of female gender, older age and lower lung function exhibited lower QOL-PCD scores in general, while
high correlations for most QOL-PCD scales with corresponding SF-36 scales were observed, in particular for physical
functioning (r = 0.78, p < 0.05).
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Conclusion: The adult version of QoL-PCD questionnaire has been translated according to international guidelines
resulting to a cross-culturally validated Greek version which exhibited moderate to good metric properties in terms
of internal consistency, stability, known-group and convergent validity.
Keywords: Primary Ciliary dyskinesia, Quality of life, Psychometric testing
Introduction
Primary Ciliary Dyskinesia (PCD) is a rare, genetically
heterogeneous disease characterized by dysfunction of
motile cilia and disruption of mucociliary clearance.
PCD patients usually suffer from chronic recurrent re-
spiratory infections, which lead to chronic destructive
airway disease, progressive loss of lung function and
structural damage of the airways (bronchiectasis). Other
manifestations of PCD include chronic wet cough, rhi-
norrhea, nasal polyps, frequent ear infections and situs
abnormalities [1].
PCD clinical manifestations [2] as well as the com-
monly recommended treatment modalities such as daily
respiratory physiotherapy and frequent or daily anti-
biotic administration [3], may impact the perceived qual-
ity of life of PCD patients. Previous studies have
demonstrated that PCD patients, as well as their family
members, may experience significant psychological
stress, emotional and social impacts [4, 5]. In an effort
to capture and access the impact of PCD from the pa-
tient perspective, a Health Related Quality of Life ques-
tionnaire (QOL-PCD) has been recently developed for
pediatric, teenager and adult PCD patients [6–9] Follow-
ing a rigorous process, which involved literature reviews,
expert panel discussions, evaluation of existing measures
and cognitive interviews, the QOL-PCD questionnaires
were developed and validated in the English language.
Subsequently, these were translated into several lan-
guages including Greek [10–13]. The QOL-PCD ques-
tionnaire has four age-specific versions (adults ≥18 years,
adolescents 13–17 years, children 6–12 years and a
parent-proxy questionnaire for children 6–12 years).
The aim of this study was to investigate, for the first
time, the metric properties of the Greek version of the




The Greek version of the adult QOL-PCD questionnaire
(available in Supplementary File 1) includes 40 questions
that compose ten sub-scales: Physical Functioning (n =
5), Vitality (n = 3), Emotional Functioning (n = 5), Health
Perception (n = 4), Treatment Burden (n = 4), Upper Re-
spiratory Symptoms (n = 4), Lower Respiratory Symp-
toms (n = 6), Role (n = 4) Social Functioning (n = 3),
Hearing Symptoms (n = 2). Higher scores in each sub-
scale represent increased HRQoL.
Translation to Greek language and cross-cultural
adaptation
The English version of the adult QOL-PCD question-
naire underwent forward translation by two independent
translators (PK, AT) that were native Greek speakers
with excellent command of the English language and
good knowledge of PCD. Both independent translators,
with the support of the team that developed the English
version then agreed to a “consensus” forward translation
that was subsequently back translated to English by a
different translator who was familiar with PCD and had
an excellent command of Greek (mother language) and
English language. The back translated version of the
Greek questionnaire was compared to the original Eng-
lish version of the questionnaire to check for differences.
After careful review, the provisional version of the ques-
tions that constituted the Greek questionnaire was
agreed through consensus. This step was followed by
one-to-one cognitive interviews of 12 adult PCD pa-
tients. The cognitive interviews were performed by a re-
spiratory nurse (PI), familiar with PCD and were
followed by one-to-one, patient-interviewer discussions
of comprehension issues and/or other obscure points.
This process aimed to ensure the questionnaire is cul-
turally acceptable, comprehensive and readable; subse-
quent minor modifications resulted in its final form. The
Greek version of the questionnaire includes a total of 40
questions, similar to the English version. A schematic
diagram of the translation process is available in Fig. 1.
Validation study
Study population
Between January 2017 and June 2019, PCD patients at-
tending the PCD clinic at Archbishop Makarios III hos-
pital in Nicosia for their routine clinical evaluations,
were asked to participate in the validation study by com-
pleting the QOL-PCD questionnaire if they fulfilled the
following inclusion criteria: (1) “definite” or “highly
likely” diagnosis of PCD according to the recent ERS
guidelines for PCD diagnosis [14] (2) age > 18 years and
(3) ability to speak and read Greek fluently. PCD diagno-
sis in Cyprus PCD Service relies on a combination of
tests, including nasal Nitric Oxide (nNO), Transmission
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Electron Microscopy (TEM), High Speed Video Micros-
copy (HSVM) and/or identification of biallelic disease-
causing mutations in one of the known PCD genes. The
diagnostic subgroup “definite PCD” refers to patients
with hallmark TEM findings and/or an identified bialle-
lic PCD genetic mutation, while the diagnostic subgroup
“highly likely PCD” refers to patients with abnormal
HSVM findings and low nNO (using a cut-off of 77 nl/
min as suggested by Leigh MW et al. 2013).
Clinical data
The anthropometric and clinical data of PCD patients
are collected in a standardized format at each visit at the
PCD clinic. Lung function assessments in terms of
Forced Vital Capacity (FVC) and Forced Expiratory Vol-
ume in the first second (FEV1) are performed with a
portable Spirometer (Vitalograph 2120) following the
2005 ERS/ATS recommendations [15] and sputum sam-
ples are collected at each visit for culture. FVC and
FEV1 measurements were expressed as z-scores pre-
dicted for the patient’s age, sex and height [16].
Statistical analysis
The validation process of the Greek version of the adult
QOL-PCD included assessment of the internal
consistency, test-retest stability, construct and conver-
gent validity for the whole questionnaire as well as for
the different subscales of the questionnaire. Internal
consistency of the QOL-PCD subscales were investigated
by Cronbach’s α values. Cronbach’s α gives a score be-
tween 0 and 1, and Cronbach’s a values > 0.70 indicate
good consistency of the questions that comprise the dif-
ferent subscales [17]. The repeatability of the QOL-PCD
(test-retest) was assessed through a second, repeated ad-
ministration of the questionnaire, a short interval (10–
14 days) after completing the baseline assessment. The
statistical intraclass correlation coefficient (ICC) criter-
ion was applied to assess the stability of the QOL-PCD
over this short time. This criterion gives values between
− 1 and + 1 and values close to 1 indicate high repeat-
ability of the questionnaire [18]. An ICC value > 0.75
demonstrates acceptable test-retest reliability across time
[19]. Construct validity was examined against a-priori
hypotheses. More specifically, we hypothesized that spe-
cific clinical features such as age, gender, FVC and FEV1
would correlate with specific scales. For example, it was
anticipated that FEV1 would correlate with physical
functioning, social functioning and lower respiratory
symptoms. Age, FVC and FEV1 were treated as categor-
ical values using the median as the cut-off value. The
Mann-Whitney U test was used to compare levels of
psychometric variables between the two groups.
To assess convergent validity, we examined the associ-
ations between the scales of QOL-PCD and the scales of
the generic 36-Item Short Form (SF-36) HR-QoL ques-
tionnaire. Pearson correlation coefficients between scales
of the two questionnaires with similar constructs were
calculated. To interpret the correlation coefficients, we
relied on Cohen’s guidelines which interpret correlations
between 0.50 and 1.00 as strong, correlations between
0.30 and 0.50 as moderate, correlations between 0.10
and 0.30 as small and correlations < 0.1 as weak [20].
Post-hoc sample size calculations were carried out using
the formula introduced by Bonnet et al. [21] for the
evaluation of internal consistency (Cronbach’s α) across
the scales of the QoL-PCD and using the G*power Soft-
ware for the subgroup comparisons performed towards
the assessment of construct validity [22].
Longitudinal construct validity
Towards assessing the longitudinal construct validity (re-
sponsiveness) of the tool, patients were asked to
complete the QOL-PCD questionnaire during their
Fig. 1 Schematic diagram of the translation process. The translation
process included forward and backward translation by independent
translators followed by one to one interviews with adult PCD
patients to ensure that the questionnaire is comprehensive and
culturally acceptable
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routine visits to the PCD clinic for a total follow-up
period of 30 months. The changes in QOL-PCD Physical
Functioning and Lower Respiratory Symptoms score be-
tween two consecutive follow-up visits were plotted
against the corresponding changes in FEV1 and FVC,
while the relationship was assessed using linear regres-
sion analysis.
Statistical analysis was conducted with the Statistical
Package of Social Sciences IBM SPSS 22 and p < 0.05
was considered to be statistically significant.
Results
Study participants
A total of fifty-two (52) patients were followed up at the
PCD clinic in Archbishop Makarios III during the period
2017–2019. Thirty-one (31) patients older than 18 years
old agreed to take part in the study. Of them, 18/31
(58.1%) were female and 14/31 (45.2%) had Situs Inver-
sus. The median age of the patients at the time of the
study was 33.6 and the median age of patient presenta-
tion to our center was 23.8. All participants were Greek-
speakers and 28/31 (90.3%) were of Greek-Cypriot ethni-
city, 2/31 (6.5%) of Arab ethnicity and 1/31 (3.2%) of
British ethnicity. Table 1 describes the demographic,
diagnostic and clinical characteristics of the participants.
Internal consistency and test-retest reliability
Overall, most QOL-PCD subscales demonstrated mod-
erate to strong internal consistency (Cronbach’s α: 0.46–
0.88 across subscales). The lowest internal consistency
was observed for Vitality (Cronbach’s α: 0.46) while the
highest was observed for Physical Functioning (Cron-
bach’s α: 0.88). All participants completed a second, re-
peated administration of the questionnaire within 2
weeks after completing the baseline assessment and test-
retest reliability assessment demonstrated good repeat-
ability for most scales (ICC: 0.67–0.91 across subscales).
The results for internal consistency and test-retest reli-
ability assessment are summarized in Table 2.
Construct validity
Based on prior hypotheses, patients were stratified by
the following variables that were anticipated to be asso-
ciated with HRQoL: Sex (male-female), Age (defined by
the median value of 33.6 years), FVC z-score (defined by
the median value of − 1.47) and FEV1 z-score (defined
by the median value of − 2.00). Females, patients > 33.6
years old and patients with lower lung function tended
to have lower QOL-PCD scores in general, although in
most comparisons statistical significance was not
achieved. More specifically, for physical functioning sub-
scale, the median score was 86.7 (IQR: 60.0–93.3) for
males and 60.0 (IQR: 38.3–88.3) for females, (pvalue for
the difference in medians = 0.060). Similarly, the median
physical functioning score for older patients was lower
(60.0, IQR: 40.0–93.3) compared to younger patients
(80.0, IQR: 54.9–93.3) (pvalue = 0.280). As hypothesized,
the median physical functioning score in patients with
FEV1 z-score < 2.00 (56.7, IQR: 34.9–80.0) was also
lower compared to the median score in patients with
FEV1 z-score ≥ 2.00 (93.3, IQR: 66.7–93.3, pvalue =
0.023). Similarly, the median score in patients with FVC
z-score < 1.47 (60.0, IQR: 33.3–80.0) tended to be lower
than in patients with higher FVC z-score (86.7, IQR:
48.3–93.3), (pvalue = 0.110). Significant differences were
also observed between younger and older patients in
terms of Social Functioning (50.0, IQR: 33.3–66.7 Vs
22.2, IQR: 0.0–44.4, pvalue = 0.022) and upper respiratory
symptoms 66.7, IQR: 52.1–83.3 Vs 58.3, IQR: 33.3–66.7,
pvalue = 0.042 as well as between high and low FEV1 z-
scores and the subscale for Lower Respiratory Symptoms
(66.7, IQR: 61.1–77.8 Vs 50.0, IQR: 38.9–65.3, pvalue =
0.016). Table 3 presents the comparisons of Physical
Functioning, Social Functioning and Lower Respiratory
Symptoms with Gender, Age, FEV1 and FVC and Sup-
plementary File 2 presents the results for all QoL-PCD
subscales.
Convergent validity
Strong correlations were observed between similar con-
structs of QOL-PCD and the SF-36 in the scales of phys-
ical functioning (r = 0.776, p < 0.05), vitality (r = 0.703,
p < 0.05) and emotional functioning/mental health (r =
0.706 p < 0.05). Upper respiratory and lower respiratory
symptoms were correlated with all SF-36 scales. Table 4
presents all correlations between QOL-PCD scales and
SF-36.
Longitudinal construct validity
There was a weak association between lung function in-
dices (FEV1 and FVC) and the QOL-PCD subscale Phys-
ical Functioning. The scatter-plots of FEV1 and FVC z-
score changes between consecutive clinic visits and cor-
responding Physical Functioning subscale changes are
presented in Fig. 2. A unit increase in FVC z-score was
associated with a 6.15 (95% CI: − 0.24 – 12.54) points in-
crease in the QOL-PCD subscale (pvalue = 0.059). Simi-
larly, a unit increase in FEV1 z-score was associated with
a 10.55 (95% CI: 2.26–18.83) points increase in the
QOL-PCD subscale (pvalue = 0.013). The relationships
between Lower Respiratory Symptoms and FVC z score
(β = 0.973, 95% CI: − 6.28 – 8.23, pvalue = 0.789) and
FEV1 z-score (β = − 5.94, 95% CI: − 15.32 – 3.45, pvalue =
0.211) were not significant.
Discussion
We present the translation and validation of the adult
QOL-PCD questionnaire into the Greek language and
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Table 1 Demographic, diagnostic and clinical characteristics of adult patients participating in the study
Parameter Adult PCD patients (n = 31)
Demographic information
Current Agea 33.6 (22.2–50.9)
Gender (female) 18/31 58.1%
Age at Presentationa 23.79 (17.8–45.1)
Situs Abnormalities 14/31 45.2%
Diagnostic characteristics
Nasal Nitric Oxide (nl/min)a 24.9 (13.0–48.0)
TEM result
Normal TEM 8/31 25.8%
ODA + IDA 9/31 29.0%
ODA only 6/31 19.4%
CP/ IDA +MD 8/31 25.8%
Other 0/31 0%
HSVM result
Normal HSVM 0/31 0%
Immotile/Almost Immotile 13/31 41.9%
Extremely stiff due to reduced ciliary bending 8/31 25.8%
Stiff Beating pattern 3/31 9.7%
Circular Pattern 7/31 22.6%
Other 0/31 0%
Clinical Characteristics
Chronic Rhinorrhoea 31/31 100%
Chronic wet cough 31/31 100%
History of NRDS 14/31 45.2%
History of nasal polyps 8/30 26.7%
History of Pneumonia 12/29 41.4%
History of Heamoptysis 3/31 9.7%
History of lung resection 5/31 16.1%
aMedian and Interquartile Range TEM Transmission Electron Microscopy, HSVM High Speed Video Microscopy, ODA + IDA Combined Outer Dynein Arm defect and
Inner Dynein Arm defect, ODA Isolated Outer Dynein Arm defect, CP Central Pair defect, IDA + MD Inner Dynein Arm and Microtubular Disorganisation defect,
NRDS Neonatal Respiratory Distress Syndrome
Table 2 Internal consistency of QoL-PCD scales measured by Cronbach’s α and test–retest reliability measured by ICC
Scale # Items Scale Median(IQR) Cronbach’s α ICC (95%)
Physical Functioning 5 80.0 (46.7–93.3) 0.880 0.910 (0.803–0.959)
Vitality 3 66.7 (44.4–77.8) 0.463 0.817 (0.598–0.916)
Emotional Functioning 5 86.7 (63.7–93.3) 0.642 0.893 (0.766–0.951)
Treatment Burden 4 66.7 (41.7–83.3) 0.809 0.670 (0.167–0.869)
Social Functioning 3 33.3 (0.0–66.7) 0.681 0.768 (0.491–0.894)
Role 4 66.7 (58.3–83.3) 0.542 0.902 (0.785–0.955)
Health Perspective 4 50.0 (41.7–66.7) 0.639 0.670 (0.277–0.850)
Upper Respiratory Symptoms 4 58.3 (41.7–83.3) 0.687 0.853 (0.678–0.933)
Lower Respiratory Symptoms 6 61.1 (44.4–72.2) 0.784 0.895 (0.769–0.952)
Hearing Symptoms 2 66.7 (58.3–100) 0.661 0.838 (0.645–0.926)
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its administration among adult PCD patients in Cyprus.
The psychometric validation of the questionnaire dem-
onstrated that it is a robust and valid instrument to
measure HRQoL in PCD patients. Overall, the Greek
version of the adult QOL-PCD questionnaire was char-
acterised by moderate to good internal consistency
across subscales (Cronbach’s a range: 0.463–0.880) and
excellent test–retest reliability across all subscales within
a two-week period (ICC range: 0.67–0.91). Compared to
generic HRQoL tools such as the SF-36, moderate to
high correlations were observed for subscales that were
measuring the same constructs such as Physical Func-
tioning, Emotional Functioning and Vitality. In relation
to the English version of the QOL-PCD questionnaire,
we observed similar psychometric properties, especially
regarding the Physical Functioning subscale which dem-
onstrated the greatest internal consistency and test-
retest reliability in both validation studies. Similarly,
convergent validity between subscales of the QOL-PCD
and SF-36 subscales was consistent in both validation
studies. In particular, subscales such as Physical Func-
tioning, Mental health and Vitality demonstrated signifi-
cant correlations, while the subscale on Social
Functioning demonstrated a non-significant correlation
in both studies. In contrast to the English version, the
Vitality subscale was characterised by low internal
consistency (Greek version Cronbach’s a: 0.463 Vs Eng-
lish version Cronbach’s a: 0.79). Low internal
Table 3 Construct validity of QoL-PCD assessed through the association of specific QoL-PCD scale values with Gender, Age, FEV1
and FVC
Parameter Physical Functioning Social Functioning Lower Respiratory Symptoms
Value Sig. Value Sig. Value Sig.
Male 86.7 (60.0–93.3) 0.060 44.4 (11.1–66.7) 0.395 66.7 (52.8–75.0) 0.258
Female 60.00 (38.3–88.3) 27.8 (0.00–55.6) 61.1 (37.5–68.1)
< 33.6 yearsa 80.00 (54.9–93.3) 0.280 50.00 (33.3–66.7) 0.022 63.9 (45.8–76.4) 0.232
> 33.6 years 60.0 (40.0–93.3) 22.2 (0.00–44.4) 61.10 (33.3–66.7)
<−2 FEV1a z-score 56.7 (34.9–80.0) 0.023 27.8 (0.00–52.80) 0.316 50.00 (38.9–65.3) 0.016
≥ − 2 FEV1 z-score 93.3 (66.7–93.3) 44.4 (22.2–66.7) 66.7 (61.1–77.8)
<−1.47 FVCa z-score 60.00 (33.3–80.0) 0.110 31.3 (0.0–55.6) 0.367 55.6 (38.9–66.7) 0.112
≥ − 1.47 FVC z-score 86.7 (48.3–93.3) 38.8 (13.9–66.7) 66.70 (51.4–77.8)
aMedian Age, Median FEV1 Z-Score, Median FVC Z-score



















0.776* 0.645* 0.351 0.407* 0.665* 0.650 0.605* 0.648*
Vitality 0.804* 0.696* 0.541* 0.298 0.703* 0.710 0.733* 0.588*
Emotional
Functioning
0.675* 0.475* 0.406* 0.333 0.711* 0.621 0.530* 0.706*
Treatment
Burden
0.113 −0.077 0.013 −0.061 −0.015 −0.050 0.066 0.033
Role 0.509* 0.469* 0.495* 0.288 0.460* 0.497* 0.403 0.403
Social
Functioning
0.325 0.240 0.251 0.132 0.175 0.238 0.157 0.224
Health
Perspective
0.307 0.209 0.268 0.461* 0.244 0.190 0.084 0.212
Upper
Respiratory
0.534* 0.577* 0.352 0.478* 0.521* 0.489* 0.401 0.485*
Lower
Respiratory
0.619* 0.644* 0.649* 0.635* 0.682* 0.571* 0.519 0.706*
Hearing
Symptoms
0.226 0.295 0.207 0.291 0.168 0.180 0.241 0.034
*Significant at the 0.05 confidence level, Highlighted cells correspond to a-priori assumed positive relationships
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consistency was driven by item #7: “You felt energetic”,
which was poorly correlated with the other two items
that were part of the Vitality subscale (item #5: You felt
tired” and item #8: “You felt exhausted”. Exclusion of
item #7 led to a Cronbach’s a equal to 0.738 for the Vi-
tality subscale.
The vast majority of PCD patients suffer from year
round rhinorrhea, nasal congestion as well as chronic
wet cough. Furthermore, compromised mucociliary
clearance frequently results in recurrent lower (pneumo-
nia) and upper respiratory infections (rhinosinusitis).
Upper airway manifestations also include nasal polyps,
serous otitis and impaired hearing [2]. The impact of
these manifastations on PCD patients, have been
assessed previously using non-PCD specific HRQoL
tools such as the St. George’s Respiratory Questionnaire
(SGRQ) and the SF-36 questionnaire, as well as by using
qualitative approaches. A recent systematic review sum-
marized the results of these early studies and highlighted
physical, emotional and social functioning as the main
areas characterizing the impact of PCD [23].
Previous studies in patients with chronic respiratory
diseases indicated that factors such as age, overall lung
function and gender may influence HRQoL. In Cystic
Fibrosis (CF), age has been shown to have a strong asso-
ciation with HRQoL subscales such as physical function-
ing, vitality and health perception [24]. A similar decline
in several scales of the SGRQ with age was also observed
in cross-sectional surveys of PCD patients in the UK
[25] and Italy [26], eventually leading to significantly
lower HRQoL compared to local general population
standards. In our adult PCD population, social function-
ing, vitality, upper respiratory symptoms and physical
functioning median scores tended to be lower in the
older compared to younger patients, although this differ-
ence did not reach statistical significance in the latter
subscale.
Female gender is a well-known predictor of adverse
disease course in CF [27, 28] and has been recently
proposed as a predictor of poor lung function in PCD
[29]. HRQoL scores in CF females have been shown
to be lower in subscales such as emotional function-
ing, social functioning and respiratory symptoms in
some studies but not in others [24]. In terms of phys-
ical functioning, female CF patients are known to
demonstrate lower scores in comparison to male pa-
tients, even after adjustments for other factors such
as FEV1, age and frequency of pulmonary exacerba-
tions [30, 31]. In line with these findings, we demon-
strated a tendency for increased disease burden
among our female PCD patients especially relating to
physical functioning and emotional functioning.
Previous CF studies also demonstrated that poorer
lung function is associated with worse physical HRQoL,
both cross-sectionally [32] and longitudinally [33]. In
particular, FEV1 was shown to be consistently associated
with physical functioning and other HRQoL scales (at a
lesser degree) across several studies involving adolescent
CF patients [24]. The relationship between FEV1 and
physical functioning was also observed among adult
PCD patients with mean scores of 41.8 and 80.5 in pa-
tients with FEV1 < 40 and > 75% respectively [8]. In our
adult PCD population the median scores for physical
functioning and lower respiratory symptoms in patients
with FEV1 z-score < 2.00 Vs FEV1 z-score ≥ 2.00 were
significantly lower, confirming the increasing burden of
the disease with progression of loss of lung function.
Interestingly, during the 30-month follow-up period, a
Fig. 2 Association of FEV1 and FVC z-score changes with Physical Functioning subscale changes. Scatter-plots of FEV1 and FVC z-score between
consecutive clinic visits and corresponding Physical Functioning subscale changes
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weak association between changes in lung function and
changes in physical functioning between clinical visits
was demonstrated. However, this association was not
evident for Lower Respiratory Symptoms, suggesting
that lung function may not be a sensitive outcome meas-
ure to capture changes in disease burden in PCD. This
was also evident in the validation study of the original
English version of the adult QOL-PCD where significant
associations between FEV1 and physical functioning
were observed in the cross-sectional analysis but not for
Lower Respiratory Symptoms [8]. In addition, lack of
standardised, national lung function reference values
may further limit the sensitivity of spirometry to capture
the variability in PCD disease burden. Perhaps a more
sensitive indicator of lung function such as the lung
clearance index could be an alternative outcome meas-
ure for short term and long-term changes in PCD dis-
ease severity [34]. Lastly, cultural differences have been
found to influence the self-perceived quality of life in
previous studies [35] but given the almost completely
homogeneous ethnic profile in our cohort, the probabil-
ity of confounding due to cultural differences is limited.
This validation study of the Greek version of the
QOL-PCD benefited from a clearly defined protocol that
was recently applied in a multicentre setting during the
validation of the English version of the QOL-PCD ques-
tionnaire and a continuous 30-month follow-up period
of the participants. In addition, participants were cases
that received a “definite” or “highly likely” diagnosis of
PCD according to the ERS diagnostic guidelines ensur-
ing diagnostic certainty in a disease that is known to be
quite heterogeneous and difficult to diagnose. Neverthe-
less, as PCD is a rare disease, the small sample size re-
mains an important limitation of this study. The small
number of participants was not though a result of non-
response or exclusion of participants as almost all
known adult PCD patients in Cyprus took part in the
study. In addition, post-hoc sample size calculations
demonstrated that for the evaluation of internal
consistency, the minimum sample size required was 20
subjects while for the subgroup analyses the minimum
sample size required was 28. All of the above confirm
that the sample was reliable, representative and reduces
selection bias. Furthermore, although low sample size
may have resulted in increased error margins in this
study, it is noteworthy that our findings are in line with
the findings of the adult QOL-PCD validation in English
language that enrolled a total of 72 patients.
Lastly, this work did not examine the effect of pul-
monary exacerbations on HRQoL in PCD as a formal
definition for pulmonary exacerbation in PCD was not
available at the beginning of this study. Since 2019, an
expert consensus statement has been proposed for PCD
[36] and future studies are expected to focus on the
responsiveness of QOL-PCD to pulmonary exacerba-
tions in PCD.
Conclusions
QOL-PCD is the first disease-specific, health related qual-
ity of life questionnaire for PCD. The adult version of
QoL-PCD has been translated according to international
guidelines resulting in a cross-culturally validated Greek
version which exhibited moderate to good metric proper-
ties in terms of internal consistency, stability, known-
group and convergent validity. The translation and valid-
ation of the QOL-PCD across different languages will
allow the consistent assessment of HRQoL in different
countries and across a larger number of PCD patients. Im-
proved understanding of PCD impact and the use of
HRQoL as a valid outcome measure in clinical trials and
clinical practice across the world will lead to improved
care for PCD patients and their families.
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